SlideShare une entreprise Scribd logo
1  sur  23
Télécharger pour lire hors ligne
The new revenue
recognition standard
for life sciences
companies
Hosted by EY Global Life Sciences
15 June 2015
Page 2
Scott Bruns
Ernst & Young LLP
Partner, Global Life Sciences
Assurance Leader
Today’s moderator
The new revenue recognition standard for life sciences companies
Page 3
Today’s presenters
Derek Kosti
International Controller
for Pfizer’s Worldwide
Biopharmaceuticals
Business
Tim Gordon
EY Global Life Sciences
Financial Accounting
Advisory Services Leader
Frederik
Schmachtenberg
EY Global Life Sciences
Assurance Resident
The information contained herein is a summary in nature. Viewers should consult their own professional
advisors to address their individual circumstances and concerns.
The new revenue recognition standard for life sciences companies
Page 4
Agenda
► The 5-step model
► Applying the 5-step model: life sciences industry-
specific examples
► Implementation considerations
The new revenue recognition standard for life sciences companies
Page 5
► Core principle: recognize revenue to depict the transfer of promised
goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange
for those goods or services
Applying the new standard: the 5-step model
Step 1: Identify the contract(s) with a customer
Step 2: Identify the performance obligations in the contract
Step 3: Determine the transaction price
Step 4: Allocate the transaction price to the performance obligations
Step 5: Recognize revenue when (or as) each performance obligation is satisfied
The new revenue recognition standard for life sciences companies
Page 6
Agenda
► The 5-step model
► Applying the 5-step model: life sciences industry-
specific examples
► Implementation considerations
The new revenue recognition standard for life sciences companies
Page 7
Example 1:
► Biotech out-licenses the rights to an investigational compound in
phase II and will perform R&D services to Pharma
► Biotech receives an upfront nonrefundable payment of $50 million,
and R&D services are billed at an agreed upon FTE rate
► Assume for this example, that the license and the R&D services are
capable of being distinct (e.g., the R&D services provided by Biotech
are not considered complex and could be performed by others in
the market)
► Question: Are the license and the R&D services distinct in the context
of the contract (i.e., separate performance obligations)?
Distinct within the context of a contract
(Part of Step 2: identify performance obligations)
The new revenue recognition standard for life sciences companies
Page 8
Distinct within the context of a contract
(Part of Step 2: identify performance obligations)
Distinct within the context of a contract
Both Boards
Clarify when a promised good or service is “separately identifiable” from other
promises in a contract (i.e., distinct within the context of the contract)
FASB
(May 2015
Exposure Draft)
Three-part change:
1. Refine the principle for determining distinct within the context of the contract
(i.e., whether the multiple promised goods or services work together to
deliver a combined output)
2. Align this principle with the standard’s three indicators for determining when
a good or service is not separately identifiable: (1) the entity is using the
goods or services as inputs to produce or deliver the combined output or
outputs specified by the customer; (2) one or more of the goods or services
significantly modifies or customizes one of the other goods or services; (3)
goods or services are highly interdependent or highly interrelated
3. Add examples
IASB
(tentative decisions)
Add examples
The new revenue recognition standard for life sciences companies
Page 9
Example 2:
► Pharma sells a product to a public hospital in a country that is in
financial difficulties in connection with the sovereign debt crisis
► Pharma has a history of delays in receipt of payment for sales due to
poor economic conditions
► On average, Pharma has days sales outstanding of 500 days and
typically receives $0.70 per dollar of the initial sales price
► Further assume that Pharma deems collection probable for $0.70 per
dollar of the initial sales price and the other criteria in Step 1 (as part
of assessing the attributes of a contract) have been met
► Question: What should be considered when evaluating whether
revenue would be recognized under:
(1) Current US GAAP and IFRS?
(2) ASC 606/IFRS 15?
Variable consideration – price concessions
(Part of Step 3: determine the transaction price)
The new revenue recognition standard for life sciences companies
Page 10
Example 2 (continued):
Variable consideration – price concessions
(Part of Step 3: determine the transaction price)
Current US GAAP and IFRS ASC 606/IFRS 15
• Pharma would need to determine
whether collectibility is reasonably
assured (US GAAP)/if it is probable that
the economic benefits will flow to the
entity (IFRS)
• If those criteria are not met, Pharma
would need to defer revenue recognition
until payments from the customer are
received, assuming the other basic
revenue recognition criteria have
been met
• If Pharma is aware of potential
collectibility issues at the onset of the
contract, but is still willing to enter into
the contract, the arrangement may
include implied price concessions.
Under the new standard implied price
concessions are considered variable
consideration and should be reflected in
the estimated transaction price.
• Once determined, the transaction price
is allocated to the performance
obligations and recognized as revenue
as control of the product transfers to
the customer
The new revenue recognition standard for life sciences companies
Page 11
Example 3:
► Biotech out-licenses the rights to an investigational compound in
phase II and will perform R&D services for Pharma
► Biotech receives an upfront nonrefundable payment of $50 million,
and R&D services are billed at an agreed upon FTE rate
► Assume for this example that the license and R&D services
are distinct
► Question: How should the amount of the transaction price allocated to
the license be recognized?
Nature of promise in granting a license of Intellectual
Property (IP) (Part of Step 5: recognize revenue)
The new revenue recognition standard for life sciences companies
Page 12
Nature of promise in granting a license of IP
(Part of Step 5: recognize revenue)
* Unless the functionality of the IP is expected to substantively change as a result of activities performed by the entity that
do not transfer a good or service and the customer is contractually or practically required to use the updated IP
The nature of an entity’s promise in granting a license of IP
Both Boards
(May 2015
FASB ED; IASB
tentative decisions)
• Activities performed by the licensor that affect the “utility” of the IP 
revenue recognized over time
• Utility = the IP’s ability to provide benefit or value
• If IP has significant standalone functionality, licensor’s activities will not
significantly affect a substantial portion of the utility of the IP  revenue
recognized at a point in time
FASB
(May 2015 ED)
IP will be classified into one of two categories:
• Functional (revenue recognition at a point in time*): IP would have
standalone functionality (e.g., drug formulas, biological compounds)
• Symbolic (revenue recognition over time): IP would not have standalone
functionality (e.g., brands, trade names, logos)
IASB
(tentative decisions)
• Only minor wording changes to expand on the principles in the new
standard
• Will not include a requirement to classify licenses of IP as either functional
or symbolic
The Boards agreed that both of their approaches generally would result in consistent answers.
The new revenue recognition standard for life sciences companies
Page 13
Example 4:
► Biotech out-licenses the rights to an investigational compound in
phase II and will perform R&D services for Pharma
► Biotech receives an upfront nonrefundable payment of $50 million,
and a quarterly payment for R&D services that are billed at an “at
market” FTE rate. Biotech is eligible to receive a 5% royalty on all
sales of a commercialized product.
► Assume for this example, that the license and R&D services are
distinct and that the stand-alone selling price of the license is the
$50 million upfront payment plus the 5% royalty rate
► Question:
► When should the 5% royalties revenue be recognized?
Sales- and usage-based royalties exception
(Part of Step 5: recognize revenue)
The new revenue recognition standard for life sciences companies
Page 14
Sales- and usage-based royalties / other license issues
(Part of Step 5: recognize revenue)
Sales- and usage-based royalties
Both Boards
(May 2015 FASB
ED; IASB tentative
decisions)
• The sales-based royalty exception would be applied to the overall royalty
stream when the predominant item to which the royalty relates is the license
of IP
• A sales-based royalty would not be partially in the scope of the sales-based
royalty constraint guidance and partially in the scope of the general variable
consideration constraint guidance
Other license issues
FASB
(May 2015 ED)
• An entity would need to consider the licenses guidance when determining
the pattern of revenue recognition for a combined performance obligation
that includes a license
• Restrictions of time, geographical region or use do not define whether a
performance obligation is satisfied at a point in time or over time or affect
how many goods or services are promised in the contract
IASB (tentative
decisions)
• No changes
• Existing guidance is sufficient
The new revenue recognition standard for life sciences companies
Page 15
Agenda
► The 5-step model
► Applying the 5-step model: life sciences industry-
specific examples
► Implementation considerations
The new revenue recognition standard for life sciences companies
Page 16
‘We don’t think there
will be significant
changes so why
should we do
anything?’
► Detail
► Documentation
► Disclosure
Impact and challenges of the new standard
The new revenue recognition standard for life sciences companies
Page 17
Customers
Impact and challenges of the new standard
Patient
Physician
Hospital
GPO
Pharmacists
Wholesalers
Specialty
distributors
Supermarkets
Government
agency
Competitors
Contract type/terms
Licenses
Direct to consumer
Return rights
Variable consideration
Rebates
Outcome based
Cost sharing
Milestones
CRO agreements
GeographyProducts
Products
Portfolio of
products
The new revenue recognition standard for life sciences companies
Page 18
Performing a diagnostic will enable
you to:
► Identify relevant revenue streams and
“unique” contracts
► Understand high-level financial and
existing in-progress project effects
► Decide on a transition method
► Prepare a detailed planning budget to
understand the level of resources
required
► Navigate stakeholder questions
regarding changes and effects
Action planning and next steps
Why start a diagnostic now?
The new revenue recognition standard for life sciences companies
Page 19
Practical challenges and questions
How to start the
assessment process?
► Team –
internal/external,
central/decentralized,
expertise needed?
► Education sessions –
how broad?
► Use of questionnaire/
surveys – how deep?
What operational
changes are we
expecting to see?
► Changes to current
contracts?
► More people outside of
finance that need to be
technically trained?
► System changes?
Challenges during
the process?
► What market coverage
is appropriate?
► How many contracts
should be reviewed?
► How much
documentation is
enough?
► Use of tools?
The new revenue recognition standard for life sciences companies
Page 20
Action planning and next steps
Before 31 December 2015
Must:
► Read the standard
and understand the
accounting
implications
► Communicate
results internally
and with other
stakeholders
► Understand what
the industry is doing
Should:
► Appoint a project
lead and cross
functional team
► Educate the
accounting and
commercial teams
► Identify revenue
streams and survey
pilot markets
► Decide on a
preferred transition
method
► Consider the tax and
systems implications
Could:
► Identify the
financial effects
► Understand the
disclosure
requirements
► Develop a data
collection plan
► Revise accounting
and procedural
policies
The new revenue recognition standard for life sciences companies
Page 21
EY resources
► EY Revenue Recognition Readiness tool
► Recent IFRS EY publications (visit ey.com/IFRS)
► Applying IFRS: A closer look at the new revenue recognition standard (June 2014)
► Applying IFRS in Life Sciences: The new revenue recognition standard – life
sciences (November 2014)
► Applying IFRS: Joint Transition Resource Group for Revenue Recognition items of
general agreement (May 2015)
► Recent US GAAP EY publications (visit ey.com/accountinglink)
► Technical Line, A closer look at the new revenue recognition standard (June 2014)
► Technical Line, The new revenue recognition standard — life sciences (August
2014)
► Joint Transition Resource Group for Revenue Recognition items of general
agreement (April 2015)
► To the Point, FASB proposes first round of amendments to its’ new revenue
recognition standard (May 2015)
The new revenue recognition standard for life sciences companies
Page 22
Scott Bruns, Global Life Sciences Assurance Leader
scott.bruns@ey.com
+1 317 681 7229
Tim Gordon, EY Global Life Sciences FAAS Leader
tim.gordon@ey.com
+1 212 773 6938
Frederik Schmachtenberg, EY Global Life Sciences Assurance Resident
frederik.schmachtenberg@ey.com
+1 312 879 5026
EY contact information
The new revenue recognition standard for life sciences companies
Page 23
Disclaimer
► These slides are for educational purposes only and are not intended, and should not be
relied upon, as accounting advice.
► This presentation is provided solely for the purpose of enhancing knowledge on tax
matters. It does not provide tax advice to any taxpayer because it does not take into
account any specific taxpayer’s facts and circumstances.
► The views expressed by the presenters are not necessarily those of
Ernst & Young LLP.
► This presentation is © 2015 Ernst & Young LLP. All Rights Reserved.
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality
services we deliver help build trust and confidence in the capital markets and in economies the world
over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders.
In so doing, we play a critical role in building a better working world for our people, for our clients and
for our communities.
EY refers to the global organization, and may refer to one or more, of the member firms, of Ernst & Young
Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company
limited by guarantee, does not provide services to clients. For more information about our organization,
please visit ey.com.
Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

Contenu connexe

Tendances

The Merchandising Evolution (and why NDC Matters)
The Merchandising Evolution (and why NDC Matters)The Merchandising Evolution (and why NDC Matters)
The Merchandising Evolution (and why NDC Matters)L.E.K. Consulting
 
Unleashing Competitiveness on the Cloud Continuum | Accenture
Unleashing Competitiveness on the Cloud Continuum | AccentureUnleashing Competitiveness on the Cloud Continuum | Accenture
Unleashing Competitiveness on the Cloud Continuum | Accentureaccenture
 
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting Group
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting GroupSalesforce Basecamp Helsinki 8.5.2018 - Boston Consulting Group
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting GroupSalesforce Finland
 
True Luxury - 2014/2015 - BCG
True Luxury - 2014/2015 - BCGTrue Luxury - 2014/2015 - BCG
True Luxury - 2014/2015 - BCGGabriela Otto
 
The 4th Annual New Mobility Study 2019
The 4th Annual New Mobility Study 2019The 4th Annual New Mobility Study 2019
The 4th Annual New Mobility Study 2019L.E.K. Consulting
 
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
TMT Outlook 2017:  A new wave of advances offer opportunities and challengesTMT Outlook 2017:  A new wave of advances offer opportunities and challenges
TMT Outlook 2017: A new wave of advances offer opportunities and challengesDeloitte United States
 
Private Sector Opportunity to Improve Well-Being
Private Sector Opportunity to Improve Well-Being Private Sector Opportunity to Improve Well-Being
Private Sector Opportunity to Improve Well-Being Boston Consulting Group
 
Navigating a digital-first home furnishings market
Navigating a digital-first home furnishings market Navigating a digital-first home furnishings market
Navigating a digital-first home furnishings market L.E.K. Consulting
 
5 Opportunities in the Nutritional Supplements Industry
5 Opportunities in the Nutritional Supplements Industry5 Opportunities in the Nutritional Supplements Industry
5 Opportunities in the Nutritional Supplements IndustryL.E.K. Consulting
 
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresMatthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresFundación Ramón Areces
 
2019 Media and Entertainment Study
2019 Media and Entertainment Study2019 Media and Entertainment Study
2019 Media and Entertainment StudyL.E.K. Consulting
 
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?Boston Consulting Group
 
Global Challengers 2018: Digital Leapfrogs
Global Challengers 2018: Digital LeapfrogsGlobal Challengers 2018: Digital Leapfrogs
Global Challengers 2018: Digital LeapfrogsBoston Consulting Group
 
McKinsey - Covid 19 - Global Auto Consumer Insights - November 2020
McKinsey -  Covid 19 - Global Auto Consumer Insights - November 2020McKinsey -  Covid 19 - Global Auto Consumer Insights - November 2020
McKinsey - Covid 19 - Global Auto Consumer Insights - November 2020Martin Hattrup
 
2018 Brand Owner Packaging Survey
2018 Brand Owner Packaging Survey2018 Brand Owner Packaging Survey
2018 Brand Owner Packaging SurveyL.E.K. Consulting
 
Australia: Taking Bigger Steps | A.T. Kearney
Australia: Taking Bigger Steps | A.T. KearneyAustralia: Taking Bigger Steps | A.T. Kearney
Australia: Taking Bigger Steps | A.T. KearneyKearney
 
The Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitThe Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitMiguel Carrasco
 

Tendances (20)

The Merchandising Evolution (and why NDC Matters)
The Merchandising Evolution (and why NDC Matters)The Merchandising Evolution (and why NDC Matters)
The Merchandising Evolution (and why NDC Matters)
 
Unleashing Competitiveness on the Cloud Continuum | Accenture
Unleashing Competitiveness on the Cloud Continuum | AccentureUnleashing Competitiveness on the Cloud Continuum | Accenture
Unleashing Competitiveness on the Cloud Continuum | Accenture
 
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting Group
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting GroupSalesforce Basecamp Helsinki 8.5.2018 - Boston Consulting Group
Salesforce Basecamp Helsinki 8.5.2018 - Boston Consulting Group
 
True Luxury - 2014/2015 - BCG
True Luxury - 2014/2015 - BCGTrue Luxury - 2014/2015 - BCG
True Luxury - 2014/2015 - BCG
 
The 4th Annual New Mobility Study 2019
The 4th Annual New Mobility Study 2019The 4th Annual New Mobility Study 2019
The 4th Annual New Mobility Study 2019
 
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
TMT Outlook 2017:  A new wave of advances offer opportunities and challengesTMT Outlook 2017:  A new wave of advances offer opportunities and challenges
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
 
Private Sector Opportunity to Improve Well-Being
Private Sector Opportunity to Improve Well-Being Private Sector Opportunity to Improve Well-Being
Private Sector Opportunity to Improve Well-Being
 
BCG Telco Sustainability Index
BCG Telco Sustainability IndexBCG Telco Sustainability Index
BCG Telco Sustainability Index
 
Great Leadership and Talent Pay Off
Great Leadership and Talent Pay OffGreat Leadership and Talent Pay Off
Great Leadership and Talent Pay Off
 
Navigating a digital-first home furnishings market
Navigating a digital-first home furnishings market Navigating a digital-first home furnishings market
Navigating a digital-first home furnishings market
 
5 Opportunities in the Nutritional Supplements Industry
5 Opportunities in the Nutritional Supplements Industry5 Opportunities in the Nutritional Supplements Industry
5 Opportunities in the Nutritional Supplements Industry
 
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresMatthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectores
 
2019 Media and Entertainment Study
2019 Media and Entertainment Study2019 Media and Entertainment Study
2019 Media and Entertainment Study
 
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?
What Does the Recovery of Demand for Urban Mobility Look Like Post-COVID-19?
 
Global Challengers 2018: Digital Leapfrogs
Global Challengers 2018: Digital LeapfrogsGlobal Challengers 2018: Digital Leapfrogs
Global Challengers 2018: Digital Leapfrogs
 
Green Venture Opportunities
Green Venture Opportunities Green Venture Opportunities
Green Venture Opportunities
 
McKinsey - Covid 19 - Global Auto Consumer Insights - November 2020
McKinsey -  Covid 19 - Global Auto Consumer Insights - November 2020McKinsey -  Covid 19 - Global Auto Consumer Insights - November 2020
McKinsey - Covid 19 - Global Auto Consumer Insights - November 2020
 
2018 Brand Owner Packaging Survey
2018 Brand Owner Packaging Survey2018 Brand Owner Packaging Survey
2018 Brand Owner Packaging Survey
 
Australia: Taking Bigger Steps | A.T. Kearney
Australia: Taking Bigger Steps | A.T. KearneyAustralia: Taking Bigger Steps | A.T. Kearney
Australia: Taking Bigger Steps | A.T. Kearney
 
The Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitThe Bionic Future - Future Work Summit
The Bionic Future - Future Work Summit
 

En vedette

Gauging Long Term Impact in the Social Sector
Gauging Long Term Impact in the Social SectorGauging Long Term Impact in the Social Sector
Gauging Long Term Impact in the Social SectorBoston Consulting Group
 
The evolving value chain in life sciences
The evolving value chain in life sciencesThe evolving value chain in life sciences
The evolving value chain in life sciencesEY
 
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...EY
 
Cultural Times - The first global map of cultural and creative industries
Cultural Times - The first global map of cultural and creative industriesCultural Times - The first global map of cultural and creative industries
Cultural Times - The first global map of cultural and creative industriesEY
 
World Economic Forum: The power of analytics for better and faster decisions ...
World Economic Forum: The power of analytics for better and faster decisions ...World Economic Forum: The power of analytics for better and faster decisions ...
World Economic Forum: The power of analytics for better and faster decisions ...PwC
 
How fit is your capital allocation strategy?
How fit is your capital allocation strategy? How fit is your capital allocation strategy?
How fit is your capital allocation strategy? EY
 
Putting digital technology and data to work for Tech CMO's
Putting digital technology and data to work for Tech CMO'sPutting digital technology and data to work for Tech CMO's
Putting digital technology and data to work for Tech CMO'sPwC
 
PwC Trends in the workforce
PwC Trends in the workforcePwC Trends in the workforce
PwC Trends in the workforcePwC
 
Moving digital transformation forward: Findings from the 2016 digital busines...
Moving digital transformation forward: Findings from the 2016 digital busines...Moving digital transformation forward: Findings from the 2016 digital busines...
Moving digital transformation forward: Findings from the 2016 digital busines...Deloitte United States
 
How Collaboration Advances Your Sustainability Efforts
How Collaboration Advances Your Sustainability EffortsHow Collaboration Advances Your Sustainability Efforts
How Collaboration Advances Your Sustainability EffortsBoston Consulting Group
 
McKinsey Quarterly 50th Anniversary Highlights
McKinsey Quarterly 50th Anniversary HighlightsMcKinsey Quarterly 50th Anniversary Highlights
McKinsey Quarterly 50th Anniversary HighlightsMcKinsey & Company
 
Findings on health information technology and electronic health records
Findings on health information technology and electronic health recordsFindings on health information technology and electronic health records
Findings on health information technology and electronic health recordsDeloitte United States
 
McKinsey Global Institute Report - A labor market that works: Connecting tale...
McKinsey Global Institute Report - A labor market that works: Connecting tale...McKinsey Global Institute Report - A labor market that works: Connecting tale...
McKinsey Global Institute Report - A labor market that works: Connecting tale...McKinsey & Company
 
From touchpoints to journeys: Seeing the world as customers do
From touchpoints to journeys: Seeing the world as customers doFrom touchpoints to journeys: Seeing the world as customers do
From touchpoints to journeys: Seeing the world as customers doMcKinsey & Company
 
Digital globalization: The new era of global flows
Digital globalization: The new era of global flowsDigital globalization: The new era of global flows
Digital globalization: The new era of global flowsMcKinsey & Company
 
Bcg Consultants Love Life
Bcg  Consultants Love LifeBcg  Consultants Love Life
Bcg Consultants Love Lifenitinagarwalin
 
The Search for Meaning in B2B Marketing
The Search for Meaning in B2B MarketingThe Search for Meaning in B2B Marketing
The Search for Meaning in B2B MarketingVelocity Partners
 
10 Powerful Body Language Tips for your next Presentation
10 Powerful Body Language Tips for your next Presentation10 Powerful Body Language Tips for your next Presentation
10 Powerful Body Language Tips for your next PresentationSOAP Presentations
 

En vedette (20)

Gauging Long Term Impact in the Social Sector
Gauging Long Term Impact in the Social SectorGauging Long Term Impact in the Social Sector
Gauging Long Term Impact in the Social Sector
 
10 Steps To Sustainability
10 Steps To Sustainability10 Steps To Sustainability
10 Steps To Sustainability
 
The evolving value chain in life sciences
The evolving value chain in life sciencesThe evolving value chain in life sciences
The evolving value chain in life sciences
 
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...
Business Pulse - Dual perspectives on the top 10 risks and opportunities 2013...
 
Cultural Times - The first global map of cultural and creative industries
Cultural Times - The first global map of cultural and creative industriesCultural Times - The first global map of cultural and creative industries
Cultural Times - The first global map of cultural and creative industries
 
World Economic Forum: The power of analytics for better and faster decisions ...
World Economic Forum: The power of analytics for better and faster decisions ...World Economic Forum: The power of analytics for better and faster decisions ...
World Economic Forum: The power of analytics for better and faster decisions ...
 
How fit is your capital allocation strategy?
How fit is your capital allocation strategy? How fit is your capital allocation strategy?
How fit is your capital allocation strategy?
 
Putting digital technology and data to work for Tech CMO's
Putting digital technology and data to work for Tech CMO'sPutting digital technology and data to work for Tech CMO's
Putting digital technology and data to work for Tech CMO's
 
PwC Trends in the workforce
PwC Trends in the workforcePwC Trends in the workforce
PwC Trends in the workforce
 
Moving digital transformation forward: Findings from the 2016 digital busines...
Moving digital transformation forward: Findings from the 2016 digital busines...Moving digital transformation forward: Findings from the 2016 digital busines...
Moving digital transformation forward: Findings from the 2016 digital busines...
 
How Collaboration Advances Your Sustainability Efforts
How Collaboration Advances Your Sustainability EffortsHow Collaboration Advances Your Sustainability Efforts
How Collaboration Advances Your Sustainability Efforts
 
McKinsey Quarterly 50th Anniversary Highlights
McKinsey Quarterly 50th Anniversary HighlightsMcKinsey Quarterly 50th Anniversary Highlights
McKinsey Quarterly 50th Anniversary Highlights
 
Findings on health information technology and electronic health records
Findings on health information technology and electronic health recordsFindings on health information technology and electronic health records
Findings on health information technology and electronic health records
 
McKinsey Global Institute Report - A labor market that works: Connecting tale...
McKinsey Global Institute Report - A labor market that works: Connecting tale...McKinsey Global Institute Report - A labor market that works: Connecting tale...
McKinsey Global Institute Report - A labor market that works: Connecting tale...
 
From touchpoints to journeys: Seeing the world as customers do
From touchpoints to journeys: Seeing the world as customers doFrom touchpoints to journeys: Seeing the world as customers do
From touchpoints to journeys: Seeing the world as customers do
 
Digital globalization: The new era of global flows
Digital globalization: The new era of global flowsDigital globalization: The new era of global flows
Digital globalization: The new era of global flows
 
Bcg Consultants Love Life
Bcg  Consultants Love LifeBcg  Consultants Love Life
Bcg Consultants Love Life
 
The Search for Meaning in B2B Marketing
The Search for Meaning in B2B MarketingThe Search for Meaning in B2B Marketing
The Search for Meaning in B2B Marketing
 
How Google Works
How Google WorksHow Google Works
How Google Works
 
10 Powerful Body Language Tips for your next Presentation
10 Powerful Body Language Tips for your next Presentation10 Powerful Body Language Tips for your next Presentation
10 Powerful Body Language Tips for your next Presentation
 

Similaire à The new revenue recognition standard for life sciences companies

20190523 sftr exec overview
20190523 sftr exec overview20190523 sftr exec overview
20190523 sftr exec overviewSilvano Stagni
 
The Shifting Pharmaceutical Industry Landscape
The Shifting Pharmaceutical Industry LandscapeThe Shifting Pharmaceutical Industry Landscape
The Shifting Pharmaceutical Industry LandscapePhil Howard
 
forrester-tei-rtd-432543
forrester-tei-rtd-432543forrester-tei-rtd-432543
forrester-tei-rtd-432543Jeremy Remus
 
Questions On Stock Valuation Of Different Companies
Questions On Stock Valuation Of Different CompaniesQuestions On Stock Valuation Of Different Companies
Questions On Stock Valuation Of Different CompaniesAmanda Reed
 
Nur 571 Generally Accepted Accounting Principles
Nur 571 Generally Accepted Accounting PrinciplesNur 571 Generally Accepted Accounting Principles
Nur 571 Generally Accepted Accounting PrinciplesLisa Chambers
 
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...Rachel Hamilton
 
Presentation: GMP Fees and Charges
Presentation: GMP Fees and ChargesPresentation: GMP Fees and Charges
Presentation: GMP Fees and ChargesTGA Australia
 
Your guide to the Patent Box and Above The Line R&D tax credit
Your guide to the Patent Box and Above The Line R&D tax creditYour guide to the Patent Box and Above The Line R&D tax credit
Your guide to the Patent Box and Above The Line R&D tax creditSteve Leith
 
The Age of Alignment Part III: Moving From Theory to Practice
The Age of Alignment Part III: Moving From Theory to PracticeThe Age of Alignment Part III: Moving From Theory to Practice
The Age of Alignment Part III: Moving From Theory to PracticePearl Meyer
 
5 things life sciences companies need to know about the R&D credit
5 things life sciences companies need to know about the R&D credit5 things life sciences companies need to know about the R&D credit
5 things life sciences companies need to know about the R&D creditGrant Thornton LLP
 
[Case Study] Launching Innocent + Developing a new product for the teeth whit...
[Case Study] Launching Innocent + Developing a new product for the teeth whit...[Case Study] Launching Innocent + Developing a new product for the teeth whit...
[Case Study] Launching Innocent + Developing a new product for the teeth whit...Riri Kusumarani
 
us-fsi-positioning-for-success-in-private-equity
us-fsi-positioning-for-success-in-private-equityus-fsi-positioning-for-success-in-private-equity
us-fsi-positioning-for-success-in-private-equityJ. Lynette DeWitt
 
Question 1 Capital Expenditure Decisions and Investment Criteria .docx
Question 1 Capital Expenditure Decisions and Investment Criteria .docxQuestion 1 Capital Expenditure Decisions and Investment Criteria .docx
Question 1 Capital Expenditure Decisions and Investment Criteria .docxIRESH3
 
Valuation of Intangibles and Trademarks / Bewertung von IP und Marken
Valuation of Intangibles and Trademarks / Bewertung von IP und MarkenValuation of Intangibles and Trademarks / Bewertung von IP und Marken
Valuation of Intangibles and Trademarks / Bewertung von IP und MarkenDr. Anke Nestler
 
FASB Proposals Affecting Government Contractors
FASB Proposals Affecting Government ContractorsFASB Proposals Affecting Government Contractors
FASB Proposals Affecting Government ContractorsDecosimoCPAs
 
Research and Development Tax Credit and Patent Box
Research and Development Tax Credit and Patent BoxResearch and Development Tax Credit and Patent Box
Research and Development Tax Credit and Patent Boxmary tierney
 
Assessing Impacts – Methodology in Practice, Cara Maguire
Assessing Impacts – Methodology in Practice, Cara MaguireAssessing Impacts – Methodology in Practice, Cara Maguire
Assessing Impacts – Methodology in Practice, Cara MaguireOECD Governance
 

Similaire à The new revenue recognition standard for life sciences companies (20)

20190523 sftr exec overview
20190523 sftr exec overview20190523 sftr exec overview
20190523 sftr exec overview
 
The Shifting Pharmaceutical Industry Landscape
The Shifting Pharmaceutical Industry LandscapeThe Shifting Pharmaceutical Industry Landscape
The Shifting Pharmaceutical Industry Landscape
 
120301 WA Business News Opinion
120301 WA Business News Opinion120301 WA Business News Opinion
120301 WA Business News Opinion
 
forrester-tei-rtd-432543
forrester-tei-rtd-432543forrester-tei-rtd-432543
forrester-tei-rtd-432543
 
Questions On Stock Valuation Of Different Companies
Questions On Stock Valuation Of Different CompaniesQuestions On Stock Valuation Of Different Companies
Questions On Stock Valuation Of Different Companies
 
Nur 571 Generally Accepted Accounting Principles
Nur 571 Generally Accepted Accounting PrinciplesNur 571 Generally Accepted Accounting Principles
Nur 571 Generally Accepted Accounting Principles
 
Handout 1 Brand Valuation workshop
Handout 1 Brand Valuation workshopHandout 1 Brand Valuation workshop
Handout 1 Brand Valuation workshop
 
Handout 1 Brand Valuation workshop
Handout 1 Brand Valuation workshopHandout 1 Brand Valuation workshop
Handout 1 Brand Valuation workshop
 
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...
Position Limits: Calculations, Overlapping Jurisdiction, EU Developments and ...
 
Presentation: GMP Fees and Charges
Presentation: GMP Fees and ChargesPresentation: GMP Fees and Charges
Presentation: GMP Fees and Charges
 
Your guide to the Patent Box and Above The Line R&D tax credit
Your guide to the Patent Box and Above The Line R&D tax creditYour guide to the Patent Box and Above The Line R&D tax credit
Your guide to the Patent Box and Above The Line R&D tax credit
 
The Age of Alignment Part III: Moving From Theory to Practice
The Age of Alignment Part III: Moving From Theory to PracticeThe Age of Alignment Part III: Moving From Theory to Practice
The Age of Alignment Part III: Moving From Theory to Practice
 
5 things life sciences companies need to know about the R&D credit
5 things life sciences companies need to know about the R&D credit5 things life sciences companies need to know about the R&D credit
5 things life sciences companies need to know about the R&D credit
 
[Case Study] Launching Innocent + Developing a new product for the teeth whit...
[Case Study] Launching Innocent + Developing a new product for the teeth whit...[Case Study] Launching Innocent + Developing a new product for the teeth whit...
[Case Study] Launching Innocent + Developing a new product for the teeth whit...
 
us-fsi-positioning-for-success-in-private-equity
us-fsi-positioning-for-success-in-private-equityus-fsi-positioning-for-success-in-private-equity
us-fsi-positioning-for-success-in-private-equity
 
Question 1 Capital Expenditure Decisions and Investment Criteria .docx
Question 1 Capital Expenditure Decisions and Investment Criteria .docxQuestion 1 Capital Expenditure Decisions and Investment Criteria .docx
Question 1 Capital Expenditure Decisions and Investment Criteria .docx
 
Valuation of Intangibles and Trademarks / Bewertung von IP und Marken
Valuation of Intangibles and Trademarks / Bewertung von IP und MarkenValuation of Intangibles and Trademarks / Bewertung von IP und Marken
Valuation of Intangibles and Trademarks / Bewertung von IP und Marken
 
FASB Proposals Affecting Government Contractors
FASB Proposals Affecting Government ContractorsFASB Proposals Affecting Government Contractors
FASB Proposals Affecting Government Contractors
 
Research and Development Tax Credit and Patent Box
Research and Development Tax Credit and Patent BoxResearch and Development Tax Credit and Patent Box
Research and Development Tax Credit and Patent Box
 
Assessing Impacts – Methodology in Practice, Cara Maguire
Assessing Impacts – Methodology in Practice, Cara MaguireAssessing Impacts – Methodology in Practice, Cara Maguire
Assessing Impacts – Methodology in Practice, Cara Maguire
 

Plus de EY

EY Price Point Q3 2022
EY Price Point Q3 2022EY Price Point Q3 2022
EY Price Point Q3 2022EY
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022EY
 
EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY
 
Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021EY
 
EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
Zahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauZahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauEY
 
Versicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftVersicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftEY
 
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...EY
 
IBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryIBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryEY
 
Fusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenFusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenEY
 
Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?EY
 
EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY
 
Riding the crest of digital health in APAC
Riding the crest of digital health in APACRiding the crest of digital health in APAC
Riding the crest of digital health in APACEY
 
EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY
 
Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken EY
 

Plus de EY (20)

EY Price Point Q3 2022
EY Price Point Q3 2022EY Price Point Q3 2022
EY Price Point Q3 2022
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022
 
EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021
 
Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021
 
EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
Zahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauZahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf Rekordniveau
 
Versicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftVersicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger Neugeschäft
 
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
 
IBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryIBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industry
 
Fusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenFusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmen
 
Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?
 
EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020
 
Riding the crest of digital health in APAC
Riding the crest of digital health in APACRiding the crest of digital health in APAC
Riding the crest of digital health in APAC
 
EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020
 
Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken
 

Dernier

Applied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxApplied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxmarwaahmad357
 
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...Sérgio Sacani
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceLayne Sadler
 
Main Exam Applied biochemistry final year
Main Exam Applied biochemistry final yearMain Exam Applied biochemistry final year
Main Exam Applied biochemistry final yearmarwaahmad357
 
Physics Serway Jewett 6th edition for Scientists and Engineers
Physics Serway Jewett 6th edition for Scientists and EngineersPhysics Serway Jewett 6th edition for Scientists and Engineers
Physics Serway Jewett 6th edition for Scientists and EngineersAndreaLucarelli
 
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPirithiRaju
 
Pests of tenai_Identification,Binomics_Dr.UPR
Pests of tenai_Identification,Binomics_Dr.UPRPests of tenai_Identification,Binomics_Dr.UPR
Pests of tenai_Identification,Binomics_Dr.UPRPirithiRaju
 
Role of Herbs in Cosmetics in Cosmetic Science.
Role of Herbs in Cosmetics in Cosmetic Science.Role of Herbs in Cosmetics in Cosmetic Science.
Role of Herbs in Cosmetics in Cosmetic Science.ShwetaHattimare
 
MARSILEA notes in detail for II year Botany.ppt
MARSILEA  notes in detail for II year Botany.pptMARSILEA  notes in detail for II year Botany.ppt
MARSILEA notes in detail for II year Botany.pptaigil2
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docxmarwaahmad357
 
M.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsM.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsSumathi Arumugam
 
Substances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestSubstances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestAkashDTejwani
 
Human brain.. It's parts and function.
Human brain.. It's parts and function. Human brain.. It's parts and function.
Human brain.. It's parts and function. MUKTA MANJARI SAHOO
 
RCPE terms and cycles scenarios as of March 2024
RCPE terms and cycles scenarios as of March 2024RCPE terms and cycles scenarios as of March 2024
RCPE terms and cycles scenarios as of March 2024suelcarter1
 
TORSION IN GASTROPODS- Anatomical event (Zoology)
TORSION IN GASTROPODS- Anatomical event (Zoology)TORSION IN GASTROPODS- Anatomical event (Zoology)
TORSION IN GASTROPODS- Anatomical event (Zoology)chatterjeesoumili50
 
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Sérgio Sacani
 
Role of herbs in hair care Amla and heena.pptx
Role of herbs in hair care  Amla and  heena.pptxRole of herbs in hair care  Amla and  heena.pptx
Role of herbs in hair care Amla and heena.pptxVaishnaviAware
 
geometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsgeometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsHassan Jolany
 

Dernier (20)

Applied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxApplied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docx
 
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...
Legacy Analysis of Dark Matter Annihilation from the Milky Way Dwarf Spheroid...
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data science
 
Main Exam Applied biochemistry final year
Main Exam Applied biochemistry final yearMain Exam Applied biochemistry final year
Main Exam Applied biochemistry final year
 
Physics Serway Jewett 6th edition for Scientists and Engineers
Physics Serway Jewett 6th edition for Scientists and EngineersPhysics Serway Jewett 6th edition for Scientists and Engineers
Physics Serway Jewett 6th edition for Scientists and Engineers
 
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdfPests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
Pests of cumbu_Identification, Binomics, Integrated ManagementDr.UPR.pdf
 
Pests of tenai_Identification,Binomics_Dr.UPR
Pests of tenai_Identification,Binomics_Dr.UPRPests of tenai_Identification,Binomics_Dr.UPR
Pests of tenai_Identification,Binomics_Dr.UPR
 
Role of Herbs in Cosmetics in Cosmetic Science.
Role of Herbs in Cosmetics in Cosmetic Science.Role of Herbs in Cosmetics in Cosmetic Science.
Role of Herbs in Cosmetics in Cosmetic Science.
 
MARSILEA notes in detail for II year Botany.ppt
MARSILEA  notes in detail for II year Botany.pptMARSILEA  notes in detail for II year Botany.ppt
MARSILEA notes in detail for II year Botany.ppt
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docx
 
M.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery SystemsM.Pharm - Question Bank - Drug Delivery Systems
M.Pharm - Question Bank - Drug Delivery Systems
 
Substances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening TestSubstances in Common Use for Shahu College Screening Test
Substances in Common Use for Shahu College Screening Test
 
Human brain.. It's parts and function.
Human brain.. It's parts and function. Human brain.. It's parts and function.
Human brain.. It's parts and function.
 
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
 
RCPE terms and cycles scenarios as of March 2024
RCPE terms and cycles scenarios as of March 2024RCPE terms and cycles scenarios as of March 2024
RCPE terms and cycles scenarios as of March 2024
 
TORSION IN GASTROPODS- Anatomical event (Zoology)
TORSION IN GASTROPODS- Anatomical event (Zoology)TORSION IN GASTROPODS- Anatomical event (Zoology)
TORSION IN GASTROPODS- Anatomical event (Zoology)
 
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
Digitized Continuous Magnetic Recordings for the August/September 1859 Storms...
 
Role of herbs in hair care Amla and heena.pptx
Role of herbs in hair care  Amla and  heena.pptxRole of herbs in hair care  Amla and  heena.pptx
Role of herbs in hair care Amla and heena.pptx
 
geometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsgeometric quantization on coadjoint orbits
geometric quantization on coadjoint orbits
 
Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...
 

The new revenue recognition standard for life sciences companies

  • 1. The new revenue recognition standard for life sciences companies Hosted by EY Global Life Sciences 15 June 2015
  • 2. Page 2 Scott Bruns Ernst & Young LLP Partner, Global Life Sciences Assurance Leader Today’s moderator The new revenue recognition standard for life sciences companies
  • 3. Page 3 Today’s presenters Derek Kosti International Controller for Pfizer’s Worldwide Biopharmaceuticals Business Tim Gordon EY Global Life Sciences Financial Accounting Advisory Services Leader Frederik Schmachtenberg EY Global Life Sciences Assurance Resident The information contained herein is a summary in nature. Viewers should consult their own professional advisors to address their individual circumstances and concerns. The new revenue recognition standard for life sciences companies
  • 4. Page 4 Agenda ► The 5-step model ► Applying the 5-step model: life sciences industry- specific examples ► Implementation considerations The new revenue recognition standard for life sciences companies
  • 5. Page 5 ► Core principle: recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services Applying the new standard: the 5-step model Step 1: Identify the contract(s) with a customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations Step 5: Recognize revenue when (or as) each performance obligation is satisfied The new revenue recognition standard for life sciences companies
  • 6. Page 6 Agenda ► The 5-step model ► Applying the 5-step model: life sciences industry- specific examples ► Implementation considerations The new revenue recognition standard for life sciences companies
  • 7. Page 7 Example 1: ► Biotech out-licenses the rights to an investigational compound in phase II and will perform R&D services to Pharma ► Biotech receives an upfront nonrefundable payment of $50 million, and R&D services are billed at an agreed upon FTE rate ► Assume for this example, that the license and the R&D services are capable of being distinct (e.g., the R&D services provided by Biotech are not considered complex and could be performed by others in the market) ► Question: Are the license and the R&D services distinct in the context of the contract (i.e., separate performance obligations)? Distinct within the context of a contract (Part of Step 2: identify performance obligations) The new revenue recognition standard for life sciences companies
  • 8. Page 8 Distinct within the context of a contract (Part of Step 2: identify performance obligations) Distinct within the context of a contract Both Boards Clarify when a promised good or service is “separately identifiable” from other promises in a contract (i.e., distinct within the context of the contract) FASB (May 2015 Exposure Draft) Three-part change: 1. Refine the principle for determining distinct within the context of the contract (i.e., whether the multiple promised goods or services work together to deliver a combined output) 2. Align this principle with the standard’s three indicators for determining when a good or service is not separately identifiable: (1) the entity is using the goods or services as inputs to produce or deliver the combined output or outputs specified by the customer; (2) one or more of the goods or services significantly modifies or customizes one of the other goods or services; (3) goods or services are highly interdependent or highly interrelated 3. Add examples IASB (tentative decisions) Add examples The new revenue recognition standard for life sciences companies
  • 9. Page 9 Example 2: ► Pharma sells a product to a public hospital in a country that is in financial difficulties in connection with the sovereign debt crisis ► Pharma has a history of delays in receipt of payment for sales due to poor economic conditions ► On average, Pharma has days sales outstanding of 500 days and typically receives $0.70 per dollar of the initial sales price ► Further assume that Pharma deems collection probable for $0.70 per dollar of the initial sales price and the other criteria in Step 1 (as part of assessing the attributes of a contract) have been met ► Question: What should be considered when evaluating whether revenue would be recognized under: (1) Current US GAAP and IFRS? (2) ASC 606/IFRS 15? Variable consideration – price concessions (Part of Step 3: determine the transaction price) The new revenue recognition standard for life sciences companies
  • 10. Page 10 Example 2 (continued): Variable consideration – price concessions (Part of Step 3: determine the transaction price) Current US GAAP and IFRS ASC 606/IFRS 15 • Pharma would need to determine whether collectibility is reasonably assured (US GAAP)/if it is probable that the economic benefits will flow to the entity (IFRS) • If those criteria are not met, Pharma would need to defer revenue recognition until payments from the customer are received, assuming the other basic revenue recognition criteria have been met • If Pharma is aware of potential collectibility issues at the onset of the contract, but is still willing to enter into the contract, the arrangement may include implied price concessions. Under the new standard implied price concessions are considered variable consideration and should be reflected in the estimated transaction price. • Once determined, the transaction price is allocated to the performance obligations and recognized as revenue as control of the product transfers to the customer The new revenue recognition standard for life sciences companies
  • 11. Page 11 Example 3: ► Biotech out-licenses the rights to an investigational compound in phase II and will perform R&D services for Pharma ► Biotech receives an upfront nonrefundable payment of $50 million, and R&D services are billed at an agreed upon FTE rate ► Assume for this example that the license and R&D services are distinct ► Question: How should the amount of the transaction price allocated to the license be recognized? Nature of promise in granting a license of Intellectual Property (IP) (Part of Step 5: recognize revenue) The new revenue recognition standard for life sciences companies
  • 12. Page 12 Nature of promise in granting a license of IP (Part of Step 5: recognize revenue) * Unless the functionality of the IP is expected to substantively change as a result of activities performed by the entity that do not transfer a good or service and the customer is contractually or practically required to use the updated IP The nature of an entity’s promise in granting a license of IP Both Boards (May 2015 FASB ED; IASB tentative decisions) • Activities performed by the licensor that affect the “utility” of the IP  revenue recognized over time • Utility = the IP’s ability to provide benefit or value • If IP has significant standalone functionality, licensor’s activities will not significantly affect a substantial portion of the utility of the IP  revenue recognized at a point in time FASB (May 2015 ED) IP will be classified into one of two categories: • Functional (revenue recognition at a point in time*): IP would have standalone functionality (e.g., drug formulas, biological compounds) • Symbolic (revenue recognition over time): IP would not have standalone functionality (e.g., brands, trade names, logos) IASB (tentative decisions) • Only minor wording changes to expand on the principles in the new standard • Will not include a requirement to classify licenses of IP as either functional or symbolic The Boards agreed that both of their approaches generally would result in consistent answers. The new revenue recognition standard for life sciences companies
  • 13. Page 13 Example 4: ► Biotech out-licenses the rights to an investigational compound in phase II and will perform R&D services for Pharma ► Biotech receives an upfront nonrefundable payment of $50 million, and a quarterly payment for R&D services that are billed at an “at market” FTE rate. Biotech is eligible to receive a 5% royalty on all sales of a commercialized product. ► Assume for this example, that the license and R&D services are distinct and that the stand-alone selling price of the license is the $50 million upfront payment plus the 5% royalty rate ► Question: ► When should the 5% royalties revenue be recognized? Sales- and usage-based royalties exception (Part of Step 5: recognize revenue) The new revenue recognition standard for life sciences companies
  • 14. Page 14 Sales- and usage-based royalties / other license issues (Part of Step 5: recognize revenue) Sales- and usage-based royalties Both Boards (May 2015 FASB ED; IASB tentative decisions) • The sales-based royalty exception would be applied to the overall royalty stream when the predominant item to which the royalty relates is the license of IP • A sales-based royalty would not be partially in the scope of the sales-based royalty constraint guidance and partially in the scope of the general variable consideration constraint guidance Other license issues FASB (May 2015 ED) • An entity would need to consider the licenses guidance when determining the pattern of revenue recognition for a combined performance obligation that includes a license • Restrictions of time, geographical region or use do not define whether a performance obligation is satisfied at a point in time or over time or affect how many goods or services are promised in the contract IASB (tentative decisions) • No changes • Existing guidance is sufficient The new revenue recognition standard for life sciences companies
  • 15. Page 15 Agenda ► The 5-step model ► Applying the 5-step model: life sciences industry- specific examples ► Implementation considerations The new revenue recognition standard for life sciences companies
  • 16. Page 16 ‘We don’t think there will be significant changes so why should we do anything?’ ► Detail ► Documentation ► Disclosure Impact and challenges of the new standard The new revenue recognition standard for life sciences companies
  • 17. Page 17 Customers Impact and challenges of the new standard Patient Physician Hospital GPO Pharmacists Wholesalers Specialty distributors Supermarkets Government agency Competitors Contract type/terms Licenses Direct to consumer Return rights Variable consideration Rebates Outcome based Cost sharing Milestones CRO agreements GeographyProducts Products Portfolio of products The new revenue recognition standard for life sciences companies
  • 18. Page 18 Performing a diagnostic will enable you to: ► Identify relevant revenue streams and “unique” contracts ► Understand high-level financial and existing in-progress project effects ► Decide on a transition method ► Prepare a detailed planning budget to understand the level of resources required ► Navigate stakeholder questions regarding changes and effects Action planning and next steps Why start a diagnostic now? The new revenue recognition standard for life sciences companies
  • 19. Page 19 Practical challenges and questions How to start the assessment process? ► Team – internal/external, central/decentralized, expertise needed? ► Education sessions – how broad? ► Use of questionnaire/ surveys – how deep? What operational changes are we expecting to see? ► Changes to current contracts? ► More people outside of finance that need to be technically trained? ► System changes? Challenges during the process? ► What market coverage is appropriate? ► How many contracts should be reviewed? ► How much documentation is enough? ► Use of tools? The new revenue recognition standard for life sciences companies
  • 20. Page 20 Action planning and next steps Before 31 December 2015 Must: ► Read the standard and understand the accounting implications ► Communicate results internally and with other stakeholders ► Understand what the industry is doing Should: ► Appoint a project lead and cross functional team ► Educate the accounting and commercial teams ► Identify revenue streams and survey pilot markets ► Decide on a preferred transition method ► Consider the tax and systems implications Could: ► Identify the financial effects ► Understand the disclosure requirements ► Develop a data collection plan ► Revise accounting and procedural policies The new revenue recognition standard for life sciences companies
  • 21. Page 21 EY resources ► EY Revenue Recognition Readiness tool ► Recent IFRS EY publications (visit ey.com/IFRS) ► Applying IFRS: A closer look at the new revenue recognition standard (June 2014) ► Applying IFRS in Life Sciences: The new revenue recognition standard – life sciences (November 2014) ► Applying IFRS: Joint Transition Resource Group for Revenue Recognition items of general agreement (May 2015) ► Recent US GAAP EY publications (visit ey.com/accountinglink) ► Technical Line, A closer look at the new revenue recognition standard (June 2014) ► Technical Line, The new revenue recognition standard — life sciences (August 2014) ► Joint Transition Resource Group for Revenue Recognition items of general agreement (April 2015) ► To the Point, FASB proposes first round of amendments to its’ new revenue recognition standard (May 2015) The new revenue recognition standard for life sciences companies
  • 22. Page 22 Scott Bruns, Global Life Sciences Assurance Leader scott.bruns@ey.com +1 317 681 7229 Tim Gordon, EY Global Life Sciences FAAS Leader tim.gordon@ey.com +1 212 773 6938 Frederik Schmachtenberg, EY Global Life Sciences Assurance Resident frederik.schmachtenberg@ey.com +1 312 879 5026 EY contact information The new revenue recognition standard for life sciences companies
  • 23. Page 23 Disclaimer ► These slides are for educational purposes only and are not intended, and should not be relied upon, as accounting advice. ► This presentation is provided solely for the purpose of enhancing knowledge on tax matters. It does not provide tax advice to any taxpayer because it does not take into account any specific taxpayer’s facts and circumstances. ► The views expressed by the presenters are not necessarily those of Ernst & Young LLP. ► This presentation is © 2015 Ernst & Young LLP. All Rights Reserved. EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities. EY refers to the global organization, and may refer to one or more, of the member firms, of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com. Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.